cabotegravir PH20

Drug information

Drug's link(s)

Not provided

Generic name

long-acting cabotegravir coadministered with recombinant human hyaluronidase PH20 (rHuPH20)

Brand names

Not provided

Compound type

Small molecule

Drug class/category

integrase strand transfer inhibitor (INSTI)

Summary

Not provided

Approval status

Unknown

Regulatory authorities

Unknown

Therapeutic area(s)

Use case(s)

Pre-Exposure Prophylaxis (PrEP)
Treatment
Prevention

Administration route

Subcutaneous, Intramuscular,

Associated long-acting platforms

Aqueous drug particle suspension

Use of drug

Ease of administration

Administered by a community health worker
Administered by a nurse
To be determined

Frequency of administration

Not provided

User acceptance

Not provided

Dosage

Available dose and strength

Not provided

Maximum dose

Not provided

Recommended dosing regimen

Not provided

Additional comments

Not provided

Dosage link(s)

Not provided

Associated compounds, formulations and regimens

Associated compounds

Compare

Cabotegravir (CAB)

Associated technologies

Not provided

Additional information

Not provided

Developer(s)

Originator

United Kingdom

ViiV Healthcare

Drug structure

Scale-up and manufacturing prospects

Scale-up prospects

Not provided

Tentative equipment list for manufacturing

Not provided

Manufacturing

Not provided

Specific analytical instrument required for characterization of formulation

Not provided

Excipients & delivery device(s)

Proprietary excipients used

Not provided

Novel excipients or existing excipients at a concentration above Inactive Ingredient Database (IID) for the specified route of administration

Not provided

Residual solvents used

Not provided

Delivery device(s)

Not provided

Safety, Efficacy and Evidence Summary

Safety

Not provided

Efficacy

Not provided

Evidence Summary

Not provided

References and relevant studies

Not provided

Description

Combination dosing regimen of cabotegravir and PH20 hyaluronidase

Brief description

The inventions herein relate to combination dosing regimen comprising administering cabotegravir and hyaluronidase. Provided are dosing regimens and combinations for treating or preventing Human Immunodeficiency Virus (HIV) infection.

Representative patent

US20230405095